307 related articles for article (PubMed ID: 14565783)
21. Ethical considerations in relation to aspirin prophylaxis.
Morgan G
Qual Prim Care; 2008; 16(6):433-40. PubMed ID: 19094419
[TBL] [Abstract][Full Text] [Related]
22. Role of Aspirin for Primary Prevention in Persons with Diabetes Mellitus and in the Elderly.
Patel NJ; Baliga RR
Curr Cardiol Rep; 2020 May; 22(7):48. PubMed ID: 32472363
[TBL] [Abstract][Full Text] [Related]
23. ASPREE-NEURO study protocol: A randomized controlled trial to determine the effect of low-dose aspirin on cerebral microbleeds, white matter hyperintensities, cognition, and stroke in the healthy elderly.
Ward SA; Raniga P; Ferris NJ; Woods RL; Storey E; Bailey MJ; Brodtmann A; Yates PA; Donnan GA; Trevaks RE; Wolfe R; Egan GF; McNeil JJ;
Int J Stroke; 2017 Jan; 12(1):108-113. PubMed ID: 27634976
[TBL] [Abstract][Full Text] [Related]
24. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
Bhatt DL; Fox KA; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Flather MD; Haffner SM; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Brennan DM; Fabry-Ribaudo L; Booth J; Topol EJ;
N Engl J Med; 2006 Apr; 354(16):1706-17. PubMed ID: 16531616
[TBL] [Abstract][Full Text] [Related]
25. A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investigator-Initiated trial.
de Waha A; Sandner S; von Scheidt M; Boening A; Koch-Buettner K; Hammel D; Hambrecht R; Danner BC; Schöndube FA; Goerlach G; Fischlein T; Schmoeckel M; Oberhoffer M; Schulz R; Walther T; Ziegelhöffer T; Knosalla C; Schönrath F; Beyersdorf F; Siepe M; Attmann T; Misfeld M; Mohr FW; Sievers HH; Joost A; Putman LM; Laufer G; Hamm C; Zeymer U; Kastrati A; Radke PW; Lange R; Cremer J; Schunkert H
Am Heart J; 2016 Sep; 179():69-76. PubMed ID: 27595681
[TBL] [Abstract][Full Text] [Related]
26. [Aspirin in cardiovascular prevention: does the approach differ by gender?].
Temizhan A
Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():2-4. PubMed ID: 18160359
[TBL] [Abstract][Full Text] [Related]
27. The role of aspirin as antiaggregant therapy in primary prevention. An update.
Jiménez-García N; de la Torre Lima J; García Alegría J
Med Clin (Barc); 2019 Oct; 153(8):326-331. PubMed ID: 31521369
[TBL] [Abstract][Full Text] [Related]
28. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
Moyad MA
Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
[TBL] [Abstract][Full Text] [Related]
29. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.
Matías-Guiu J; Ferro JM; Alvarez-Sabín J; Torres F; Jiménez MD; Lago A; Melo T;
Stroke; 2003 Apr; 34(4):840-8. PubMed ID: 12649515
[TBL] [Abstract][Full Text] [Related]
30. Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?
Patrono C
Eur Heart J; 2013 Nov; 34(44):3403-11. PubMed ID: 23771843
[TBL] [Abstract][Full Text] [Related]
31. A randomised controlled trial of low-dose aspirin for the prevention of fractures in healthy older people: protocol for the ASPREE-Fracture substudy.
Barker AL; McNeil JJ; Seeman E; Ward SA; Sanders KM; Khosla S; Cumming RG; Pasco JA; Bohensky MA; Ebeling PR; Woods RL; Lockery JE; Wolfe R; Talevski J;
Inj Prev; 2016 Aug; 22(4):297-301. PubMed ID: 26002770
[TBL] [Abstract][Full Text] [Related]
32. An aspirin a day? Aspirin use across a spectrum of risk: cardiovascular disease, cancers and bleeds.
Kolber MR; Korownyk C
Expert Opin Pharmacother; 2014 Feb; 15(2):153-7. PubMed ID: 24206142
[TBL] [Abstract][Full Text] [Related]
33. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.
Scheiman JM; Herlitz J; Veldhuyzen van Zanten SJ; Lanas A; Agewall S; Nauclér EC; Svedberg LE; Nagy P
J Cardiovasc Pharmacol; 2013 Mar; 61(3):250-7. PubMed ID: 23188121
[TBL] [Abstract][Full Text] [Related]
34. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework.
Lancet; 1998 Jan; 351(9098):233-41. PubMed ID: 9457092
[TBL] [Abstract][Full Text] [Related]
35. Aspirin for primary prevention: yes or no?
Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
[TBL] [Abstract][Full Text] [Related]
36. A short-term risk-benefit analysis of occasional and regular use of low-dose aspirin in primary prevention of vascular diseases: a nationwide population-based study.
Wu IC; Hsieh HM; Wu MT
BMJ Open; 2015 Jan; 5(1):e006694. PubMed ID: 25575876
[TBL] [Abstract][Full Text] [Related]
37. Aspirin for primary prevention of cardiovascular disease?
Drug Ther Bull; 2009 Nov; 47(11):122-5. PubMed ID: 19887685
[TBL] [Abstract][Full Text] [Related]
38. Appropriate aspirin use for primary prevention of cardiovascular disease.
Miser WF
Am Fam Physician; 2011 Jun; 83(12):1380-6. PubMed ID: 21671538
[No Abstract] [Full Text] [Related]
39. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
Bartolucci AA; Howard G
Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
[TBL] [Abstract][Full Text] [Related]
40. [Use of aspirin in diabetic patients].
Türkoğlu S; Abaci A
Anadolu Kardiyol Derg; 2007 Dec; 7 Suppl 2():5-8. PubMed ID: 18160360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
